RxDoctor Payments DataLook up a doctor →

Jontel Pierce, MD

Neurology · Houston, TXNPI 1154686061

Payments from drug & device makers

$684,850in general payments, 2019–2025

Across 179 payments — averaging $3825.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$348K
  • GSK$169K
  • Sage Therapeutics, LLC$163K
  • Livanova USA, Inc.$1K
  • AbbVie$862
  • UCB, Inc.$338
  • plus $2K from 31 others

What the payments were for

  • Travel & lodging$1,03420%
  • Food & beverage$4,21180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$684,850 in reported general payments places this provider in the 95th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$26,136
Medicare patients
73
Services billed
205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5018$319,961
MayzentSiponimod11$107,746
Ajovy AutoinjectorFremanezumab-Vfrm14$10,060
Aimovig AutoinjectorErenumab-Aooe11$7,724
Emgality PenGalcanezumab-Gnlm11$7,399
Pregabalin41$2,673
Levetiracetam41$1,908
Lacosamide26$1,452
Oxcarbazepine13$671
Donepezil Hcl59$637
Divalproex Sodium ErDivalproex Sodium13$567
Nortriptyline Hcl22$342
Eszopiclone13$327
Gabapentin29$283
Baclofen16$261

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisMayzent$347,580$107,74611 claims
Upsher-smith Laboratories LLCTopiramate$38$13016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,246 neurology providers in Texas.

Other neurology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →